| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T90553 | ||||
| Target Name | MARK3 | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | UCN-01 | Drug Info | IC50 = 27 nM | [552220] | |
| Action against Disease Model | UCN-01 | Abrogated DNA damage-induced G2 arrest, leading to mitotic entry and subsequent cell death. | [537564] | Drug Info | |
| The Effect of Target Knockout, Knockdown or Genetic Variations | Tau?knockout mice show behavioural impairments and structural abnormalities with advancing age,suggesting that long?term suppression of tau as a therapy for tauopathies might befraught with complications | [552220] | |||
| References | |||||
| Ref 552220 | The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 2000 Apr 15;60(8):2108-12. | ||||
| Ref 537564 | Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.